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Abstract Sarcopenia—the age-related loss of skele-
tal muscle mass and strength—is a major public health
issue. Sarcopenia is associated with an increased risk
of falls, disability, dependency, institutionalization,
hospital stay and early death. Finding interventions to
stabilize, reverse or prevent sarcopenia is therefore a
key goal for clinical ageing research. If patients are to
eventually benefit from discovery science on ageing
skeletal muscle, we need to build a translational
pipeline that facilitates progress from laboratory
science and epidemiology, through feasibility testing
to early-phase, and eventually late-phase clinical
trials. A number of barriers need to be overcome to
make this pipeline work—in particular challenges
around identifying people with sarcopenia in routine
clinical practice, ensuring that we study patients with
clearly defined sarcopenia rather than related condi-
tions such as functional impairment, developing
capacity to run trials for older people, and selecting
trial outcomes of relevance to older people with
multimorbidity. A further key point is that interven-
tions should ideally have pleiotropic actions—i.e.
beneficial actions across multiple organ systems,
rather than treating sarcopenia alone. Such pleiotropic
interventions may be the only way to avoid the perils
of polypharmacy and drug interactions that bedevil
care for many older people. Maximising the potential
for scientific discoveries in the biology of ageing
muscle to improve health requires that discovery
scientists, translational clinical scientists and clini-
cians come together to exchange findings and shape
each others ideas within a shared culture.
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Introduction
Sarcopenia is a relative newcomer in the diagnostic
pantheon compared with many illnesses that accom-
pany advanced age. Although the loss of muscle mass
and strength that define sarcopenia were recognised in
ancient times, the modern use of the term dates back
only to the late 1980s (Rosenberg 1997), and the use of
sarcopenia as a diagnostic term is even more recent,
receiving an ICD-10 code as recently as 2016. The
definition continues to undergo refinement (Cruz-
Jentoft et al. 2010, 2018; Studenski et al. 2014).
Despite this, considerable progress is being made in
understanding both the epidemiology and pathophys-
iology of sarcopenia (Sayer et al. 2013), and in
common with many other diseases such as dementia
that are more common with advanced age, there is now
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a realisation that sarcopenia may not be an
inevitable consequence of ageing.
It is now clear that sarcopenia is common, affecting
5–10% of the general population aged over 65, but up
to 50% of nursing home residents (Mayhew et al.
2018; Shen et al. 2018). Sarcopenia is associated with
a wide range of serious consequences for older
people—falls, hospitalisation, longer length of stay
in hospital, a greater need for care including nursing
home care, and finally earlier death (Beaudart et al.
2017). Sarcopenia is costly—the estimated cost to the
UK National Health Service is £2.5 billion per year
(Pinedo-Villanueva et al. 2018). Sarcopenia is there-
fore an important condition for us to understand,
diagnose and treat. Although there is much still to
learn about the aetiology and pathophysiology of
sarcopenia, a range of culprit biological systems are
under active investigation, including pertubations in
hormonal systems, chronic inflammation, mitochon-
drial function, and networks of adipokines and
myokines (Morley 2016).
These insights are starting to suggest a wide range
of potential therapeutic targets that will require testing
in clinical studies including trials. Doing so will not be
straightforward, and this paper discusses both the
barriers to conducting such trials, and gives some
suggestions for how we can make progress so that the
burgeoning insights from discovery science make their
way successfully into clinical practice.
What are the key barriers to translating discovery
science into clinical treatments for sarcopenia?
General considerations for trials for older people
Signal to noise ratio
Trials in older people are difficult, and these difficul-
ties have deterred investigators in many other organ-
specific conditions from designing and delivering
clinical trials for older people. To detect a statistically
significant treatment effect, trials need to recruit
sufficient participants to differentiate the effect (sig-
nal) from the noise (variation). For older people, this
signal to noise ratio is low—most biological measures
are more heterogeneous in old age that in younger
people, and the trajectory followed by older people is
rarely stable. Illness, and the recovery from illness, are
common in older people. This is particularly the case
for sarcopenia, which is frequently accompanied by
multiple other conditions (Volpato et al. 2014). A
related issue is that older people with multiple
conditions are more likely to die or become too ill to
continue during a trial; failure to undergo follow up
measurements reduces trial power and requires larger
initial sample sizes.
Attempts to exclude those with comorbidity are
counterproductive; not only does this approach ham-
per trial recruitment; it leads to trial populations which
are unrepresentative of the broader population
(McMurdo et al. 2005). This lack of generalisability
for trial results is a major barrier to the uptake of trial
findings into clinical practice—clinicians conclude
that the trial participants ‘‘aren’t the patients we care
for’’. Heart failure, hypertension, diabetes and cancer
are just some of the disease areas that have previously
been affected by this lack of generalisability of trial
results (Cherubini et al. 2011; Conroy et al. 2018;
Cruz-Jentoft et al. 2013; Townsley et al. 2005). Some
of the above problems can be overcome by increasing
initial sample sizes, but the additional time and cost,
large number of adverse events and dropouts (usually
unrelated to the trial intervention) have made trials for
older people unattractive to both commercial and
academic investigators to date.
Multimorbidity and the choice of outcomes
Multimorbidity is the norm for older people (Barnett
et al. 2012), yet most clinical medical research
focusses on single conditions, often affecting a single
organ. Such an approach is once again at variance with
the lived experience of patients, but is also at variance
with the needs of clinicians and policymakers. Clinical
guidelines—often the endpoint of a long research
process—are mostly based on single conditions, with
little attention paid to how such guidelines overlap or
conflict with each other. For older people with
multiple conditions, applying multiple sets of guide-
lines leads to an intolerable treatment burden (Buffel
du Vaure et al. 2016), polypharmacy (with a danger of
multiple side effects and drug interactions) (Scottish
Government 2018) and frankly conflicting advice
(Hughes et al. 2013).
If we are to avoid pursuing research that ends with
such an unhelpful evidence base, we need to ensure
that trials for sarcopenia are designed differently. This
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applies as much to early-phase translational work as to
later-phase trials. It is often argued that homogeneity
and a lack of confounding factors are important when
attempting to demonstrate proof of concept or efficacy
(Kent and Kitsios 2009). This may indeed make it
easier to demonstrate efficacy, and avoids the issue
that other diagnoses may be more important drivers of
impairment for some individuals than sarcopenia.
However, if a potential treatment cannot show proof-
of-concept in a group of older people with multiple
other conditions, there is little point in taking the
intervention forward for testing in large-scale, later-
phase trials.
Although selecting the right population to study is
important, selecting the right outcomes is also key.
Research into single organ conditions has tended to
select outcomes that focus only on the function of that
organ, missing both potential harms and the overall
balance of risk and benefit to patients. Such an
approach is worsened by the use of surrogate out-
comes—intermediate measures that are thought to be
related to clinically important outcomes. Use of such
outcomes requires careful validation and interpreta-
tion to avoid drawing misleading conclusions. The
example of glycosylated haemoglobin (HbA1c) in
diabetes mellitus is instructive in this regard. Although
HbA1c levels are predictive of microvascular out-
comes (such as retinopathy and neuropathy), they bear
little relation to macrovascular outcomes (such as
heart disease and stroke). Furthermore, a narrow focus
on reducing HbA1c fails to capture other important
harms, including hypoglycaemia and its attendant
consequences such as falls and cognitive impairment.
Despite these limitations, ability to reduce HbA1c has
been used as a regulatory approval criterion for new
diabetes medications for many years, and many trials
in diabetes still focus on whether interventions reduce
HbA1c, yet this approach gives a very incomplete
picture of the overall harms and benefits of interven-
tions. It is only in the last few years that regulators
have started to demand large trials measuring cardio-
vascular endpoints for new diabetes medications
(Cefalu et al. 2018).
The situation is similar for studies in the field of
sarcopenia. Many studies focus on muscle mass, yet
increasing muscle mass without an improvement in
strength or performance is unlikely to be relevant to
older people. Muscle strength is a much better
predictor of the ability to perform activities of daily
living—yet even this approach does not enable the
potential downsides of therapy (which may affect
systems outwith the musculoskeletal system) to be
captured and compared. Physical function and quality
of life are outcomes that older people value most
(Roberts et al. 1994); it therefore follows that these are
the outcomes that any intervention should be attempt-
ing to improve—and thus should be key outcomes in
clinical trials for sarcopenia interventions.
Physical, social and cognitive impairment
Recruiting older people to clinical trials takes addi-
tional time and specific skills on the part of investi-
gators and research teams. As argued above, recruiting
healthy older people to trials does not lead to a
representative trial population. However, many trials
are based in large hospitals, often with difficult
transport links and long walks required to reach the
study centre after arriving at the hospital. Hospitals are
busy, confusing places even for those with intact
cognition and no impairment of vision and hearing.
Many older people find that their social network has
become eroded through death and incapacity, and thus
lack people who can support them to attend study
visits. Once at the study centre, older people may have
to deal with long, dense documents such as study
information sheets, and endure long study visits of
several hours. All of these factors act as potential
disincentives to trial participation, but also provide
investigators with potential ways to improve the trial
experience for older people by providing taxi trans-
port, siting research centres within easy walking or
wheelchair distance, and minimising both study visit
duration and the number of outcomes measured.
Specific issues in the design and execution
of sarcopenia trials
Studies need to recruit populations with a defined
diagnosis of sarcopenia
Sarcopenia as an entity is a relatively recent arrival in
the research and clinical landscape, and so it is perhaps
unsurprising that most clinical studies to date have not
been conducted in populations with sarcopenia. Whilst
there is clearly overlap between sarcopenia and other,
more commonly measured constructs (e.g. frailty and
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functional impairment) (Fig. 1), the degree of overlap
is not usually clear from published reports. This
matters, because interventions that might work in the
specific disease state of sarcopenia might do nothing in
healthy older people, or in those with for example
preserved muscle mass but impaired function. The
converse is also true. At the very least, effects might be
diluted if a study population has only a proportion with
sarcopenia; such studies would then require larger
number of participants to demonstrate differences
between intervention and control groups.
Finding people with sarcopenia is challenging
The diagnosis of sarcopenia is not often made in
current clinical practice—even by geriatricians, who
specialise in the care of older people. A diagnostic
code (ICD-10) code did not exist for coding sarcope-
nia until late 2016, and even when sarcopenia is
diagnosed, it is poorly recorded in both paper and
electronic records. A vicious cycle currently exists
within clinical practice; there is a lack of interventions
to prevent or reverse sarcopenia beyond resistance
training, thus there is little added value to clinicians in
making or recording the diagnosis as doing so does not
change treatment. Although measuring grip strength,
walk speed or chair stand time is simple and quick to
do in clinical practice, the need to measure muscle
mass to make a diagnosis of sarcopenia is a barrier to
making the diagnosis; imaging techniques such as
DEXA, CT or MRI scanning are expensive and non-
portable; use of techniques such as bioimpedance
measurement require careful validation of measure-
ment tools in specific populations (Reiter et al. 2019)
to generate useful results. The most recent sarcopenia
diagnostic guidelines recognise this barrier to diagno-
sis and allow a diagnosis of ‘probable sarcopenia’
(Cruz-Jentoft et al. 2018) based solely on low muscle
strength, but this approach risks altering the target
population for trials and makes comparison with
studies using a strength plus mass-based diagnosis
difficult.
For research teams, this lack of routine diagnosis
and recording means that it is necessary to screen large
numbers of older people for low muscle mass and
strength when conducting clinical research in sar-
copenia (Marzetti et al. 2018). Efficient systems to find
people with sarcopenia are therefore needed and
potential solutions are discussed later in this article.
Further disincentives exist for commercial partners to
engage in sarcopenia research; the diagnosis cannot
currently be used to base marketing authorisation for
new drugs, and those seeking to develop new agents
are forced to use other conditions (e.g. falls or hip
fracture) as endpoints to allow marketing authorisa-
tion. Work is ongoing between research teams and
regulators including the US Food and Drug Admin-
istration and the European Medicines Agency (Le
Lain et al. 2017) to define endpoints for sarcopenia
trials that would enable regulatory approval of new
therapeutics.
A related, but distinct set of challenges face
researchers who wish to prevent the development of
sarcopenia—an approach that is likely to be essential
if we are to relieve the burden of sarcopenia at the
population level. More work is needed on factors that
predict the future onset of sarcopenia to enable
selection of individuals most likely to benefit from
prevention, and similar considerations to those dis-
cussed above apply to the choice of outcome
Fig. 1 Difference in target populations for muscle studies in older people
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measures. The need for short-term biomarker predic-
tors of response is arguably even greater for preven-
tion trials, as interventions to prevent sarcopenia may
require to be given for very long periods of time (years
to decades) if the life-course trajectory of skeletal
muscle decline is to be usefully modified (Sayer et al.
2013).
Steps to bridging the gap between laboratory
science and clinical practice
How then can we develop programmes of research in
sarcopenia that mitigate or circumvent the issues
described above, and that enable faster, smoother
translation of the wealth of discovery science findings
into new treatments? The first step is to get people
talking to each other—epidemiologists, discovery
scientists, trialists and clinicians. As with so many
areas of medicine and science, silo working is
prevalent (Editorial 2016), leading to lost opportuni-
ties to join up different phases of work, to learn from
different perspectives, and to avoid waste, dead ends
and duplication. Joint meetings, interdisciplinary
research groups, and embedding science in clinical
teaching at all phases of training, are all potentially
useful initiatives. Improved communication will
undoubtedly help to ensure a consistent approach to
sarcopenia research from bench to bedside.
Studying the right populations
If we really want to know about the epidemiology,
pathophysiology and treatments for sarcopenia, we
need to study people with sarcopenia—not related but
distinct populations such as those with functional
impairment. Only then can we have confidence in our
insights, and an expectation that the findings will be
relevant to a patient with sarcopenia. In addition, we
need to embrace the multimorbidity that inevitably
accompanies sarcopenia. Failure to do so will render
our work irrelevant to patients and their clinicians.
Clinical studies—even very early phase experimental
medicine studies—need to enrol patients with multi-
morbidity, as the presence of these other disease states
may underpin, or at least modify, the phenotypic
expression of sarcopenia. An example would be the
role of chronic inflammation, posited to be important
in sarcopenia. Many diseases (e.g. chronic obstructive
pulmonary disease, atherosclerotic disease) are impli-
cated in chronic inflammatory states, and a full
understanding of how chronic inflammation con-
tributes to sarcopenia requires study in patients with
diseases that contribute to that chronic inflammatory
state.
What would an ideal intervention look like?
Next, we need to consider what a good intervention for
sarcopenia would look like. Selection of interventions
for study needs to be informed by plausible biological
mechanisms, but other considerations are important in
selection at an early stage in the translational pathway.
Low cost, ease of administration (ideally once every
few months, but certainly not multiple times a day),
ability to formulate an oral preparation, and a lack of
adverse effects are all important factors.
Perhaps the most valuable property for candidate
interventions in older people however is that of
pleiotropic benefit. This goes rather against the current
paradigm for intervention development, where multi-
ple interventions are developed for each single disease
state (Witham and George 2014). This paradigm has
led to the problem of polypharmacy—multiple dis-
eases require multiple medications, each one of which
carries a range of side effects and drug interactions.
Unsurprisingly, polypharmacy is associated with high
rates of adverse events, many of which are
attributable to medication use and not just to the
underlying disease states. For many older patients,
fewer, not more medications may be needed to
improve overall health and quality of life (Scottish
Government 2018). Medications with pleiotropic
benefits are likely to be those that target fundamental
biological processes of ageing that underlie multiple
disease states. Such interventions thus have the
potential to provide beneficial effects across several
diseases from a single agent. To a limited extent, such
agents do exist already—beta blockers are used to treat
heart failure, hypertension and atrial fibrillation for
example; and other candidate pleiotropic agents (e.g.
allopurinol, metformin) are under investigation
(Barzilai et al. 2016; Mackenzie et al. 2016). Candi-
date interventions for sarcopenia that also benefit bone
health, cardiovascular health and other organ systems
are a goal worth working towards.
There is plenty of scope here for different phases of
the research process to inform each other—the results
123
Biogerontology
of clinical trials or observations can suggest new
targets to research, just as fundamental biological
research can help to both inform the choice of
interventions to test and the characteristics of patients
most likely to benefit from a particular intervention.
Such a virtuous circle however requires clinicians,
clinical researcher and discovery scientists not only to
talk to each other, but to learn each others’ languages
and cultures (Coller 2008).
Selecting the right outcomes
Outcomes in clinical studies need to be informed by
what patients, but also clinicians, health and social
services deem important. This too has an impact on
preclinical science—for instance if an intervention is
found to improve muscle mass but not strength in
preclinical work, the case for translating these findings
into even early clinical studies is likely to be weak, and
alternative approaches should be researched. Different
types of outcomes are however likely to be appropriate
for different phases of trial—early phase trials are
likely to need to focus on measures relevant to the
biological target of interventions, intermediate phase
trials on physical performance, but later phase trials
need to focus on physical function in daily life,
together with outcomes such as falls, healthcare
utilisation and the need for social care, as has been
argued elsewhere (Kilsby et al. 2017). Finding reliable
surrogate biomarkers that predict longer-term
response to treatment in sarcopenia trials is also
essential if we are to deliver cost-effective, early-
phase trials in a timely manner.
Building the capacity to deliver clinical research
in sarcopenia
Finally, we need to address the challenges to finding
and recruiting older people with sarcopenia into trials
and other clinical studies. Efficient pathways to
recruitment are needed, which are likely to be
multistep, involving targeted searches of electronic
databases, followed by prescreening [e.g. using the
SARC-F questionnaire (Malmstrom and Morley
2013)]. Given the difficulties inherent in this process,
the creation of registries of patients with sarcopenia is
an attractive solution; one that is now being explored
both in the UK and in mainland Europe. Such
registries would comprise detailed phenotypic data
including muscle mass, strength and physical perfor-
mance, together with pre-consent from patients to be
contacted when research that is suitable for them to
participate in becomes available. Such an approach
has worked well for other musculoskeletal diseases
(Thompson et al. 2017) and may be a way to overcome
many of the hurdles to rapid, efficient trial recruitment
in sarcopenia. The limited life and health expectancy
of those with sarcopenia presents the disease registry
model with a challenge however; such registries will
require constant recruitment effort to replace people
who die or become to unwell to participate.
Such registries on their own will not be enough
though. We also need to build networks of research-
engaged clinicians to help recruit to, and run, clinical
studies, to fund such studies adequately, and to
develop more trialists with the expertise to design
and manage trials for older people. Engaging clini-
cians in the research process will also help to ensure
that research results are taken up into clinical practice
more quickly. All of this will require investment as
well as training, but this final piece of the jigsaw is
essential if the knowledge that we are now accruing
from discovery science in musculoskeletal ageing is to
translate successfully to better treatment for
sarcopenia.
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